Calendario›NMRA›NMRA-323511

NMRA-323511

Study to Evaluate the Effects of NMRA-323511 Among Healthy Elderly and Adults With Agitation Associated With Dementia Due to Alzheimer's Disease

Ensayo de Neumora Therapeutics, Inc. en Alzheimer's Disease · Healthy Elderly (del registro, en inglés).

Más ensayos de: Enfermedad de Alzheimer.

Fase

Fase 1

Estado

Completado

Participantes

87

previstos

Centros

26

Fin del objetivo primario

nov 2025

fecha real

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, doble ciego. Comenzó en jul 2024.

Qué mide

Part A: Safety and Tolerability Assessments Based on Treatment Emergent Adverse Events (TEAEs) and Validated Clinical Scales (del registro, en inglés) (hasta 53 dias)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis study consists of 2 parts, Part A and Part B. Part A is a single center, randomized, double-blind, placebo-controlled cohort designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of NMRA-323511 among healthy elderly. Part B is a multicenter, randomized, double-blinded, placebo-controlled, parallel-group cohort to evaluate the safety, tolerability, and efficacy of NMRA-323511 among adults with Agitation Associated with Dementia due to Alzheimer's Disease. Part A consists of a Screening Period (up to 28 days), a 10-day Treatment Period, and a 10- day Follow-up clinic visit after last dose of study treatment. Part B consists of a Screening Period (up to 28 days), an 8-week Treatment Period, and a 10-day Follow-up clinic visit after last dose of study treatment.

Más ensayos de NMRA

Todos los de NMRA, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT06546995), actualizada en may 2026.